ADIPOQ and myeloid sarcoma: The significant reduction in leptin and increase in adiponectin levels reported by Brenton et al. suggest that KDs may favorably alter the adipokine profile, potentially contributing to reduced systemic inflammation and improved metabolic health in MS patients [9].